Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist metabolism program Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in th...
Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.
While not a mind-blowing move, it is good to see that the Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ:CRBP ) share...
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.
Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q3 sales of $1.23 million. Earnings fell to a loss of $33.97 million, resulting in a 10.92% decrease from last quarter. Corbus Pharmaceuticals collected $286.35 thousand in revenue during Q2, but reported earnings showed a $38.14 million loss.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher R...
During Q3, Corbus Pharmaceuticals (NASDAQ: CRBP) brought in sales totaling $1.23 million. However, earnings decreased 10.92%, resulting in a loss of $33.97 million. Corbus Pharmaceuticals collected $286.35 thousand in revenue during Q2, but reported earnings showed a $38.14 million loss.What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. ...
* Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on ...
Shares of Corbus Pharmaceuticals are down about 5.7% in pre-market trading on Wednesday after reporting lower-than-expected 3Q results. The pharma giant posted a loss of $0.43 per share, which was larger than the loss of $0.41 per share expected by analysts and compared to the year-ago loss of $0.32.3Q revenues of $1.23 million also missed the consensus estimates of $3.24 million and declined 52.5% year-over-year, due to “revenue recognized under the Cystic Fibrosis Program Related Investment Ag...